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and knee pain (r=0.598, p=0.01), stiffness (r=0.525, p=0.025)
and function (r=0.689, p=0.002) as determined by regression
analyses and presented in Figures 1, 2 and 3, respectively.
Figure 1. Pain Score vs serum CS846.
Figure 2. Stiffness Score vs serum CS846.
Figure 3. Function Score vs serum CS846.
All of these results suggest that those with a higher attempt at
abnormal cartilage synthesis have more severe symptoms than
those with lower levels abnormal cartilage repari. COMP levels
reﬂecting the amount of cartilage degeneration did not appear to
correlate with any WOMAC symptoms.
Conclusions: Knee pain, stiffness and physical function appear
to be related to serum CS846 levels suggesting that symptoms
are worse in those patients with greater abnormal cartilage
synthesis. These results may suggest that CS846 is a sensitive
clinical outcome and may be useful in trials of knee OA. There
was no signiﬁcant relationship between knee symptoms and
serum COMP level and this may partially be expained by the
fact that there was a rather large variation in COMP levels in this
population (mean 9.85 µg/L, SD=8.27 µg/L). In addition, these
serum levels were acquired at only one time point while symptom
outcomes reﬂected pain, stiffness and function over a 48 hour
period.
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ADIPONECTIN AND RESISTIN SERUM LEVELS IN
PATIENTS WITH EROSIVE AND NON-EROSIVE
OSTEOARTHRITIS OF THE HANDS
L. Šenolt1, H. Hulejová1, L. Ošlejšková1, M. Braun1,
M. Haluzík2, K. Pavelka1
1Institute of Rheumatology, Prague, Czech Republic; 2Internal
department, Prague, Czech Republic
Purpose: Adiponectin and resistin, adipocyte-derived peptides,
have been previously shown to be implicated in the pathogenesis
of obesity-related diseases. Obesity is suggested as one of the
risk factors for the development of osteoarthritis (OA) at various
sites in middle aged women. The aim of this study was to
compare serum adiponectin and resistin levels between female
patients with erosive osteoarthritis (EOA) and non-erosive OA of
the hands.
Methods: Seventy-four female patients with OA of the hands
according to ACR criteria were enrolled into this study. The ﬁrst
study group consisted of patients with EOA (n=48) and second
of non-erosive OA of the hands (n=26). Adiponectin and resistin
concentrations were analyzed by ELISA assays. Systemic in-
ﬂammation was measured by high-sensitivity C-reactive protein
(hs-CRP).
Results: Both groups were similar in terms of age and body
mass index (BMI). None of the adipocytokines correlated with
age or BMI. Mean CRP did not differ between patients with EOA
and non-erosive OA of the hands (1.78±1.22 vs. 1.87±1.61
mg/l, p=0.82). The level of serum adiponectin was signiﬁcantly
higher in erosive than in non-erosive group (28.7±13.14 vs.
21.25±11.40 µg/ml, p=0.03). On the other hand resistin levels
did not show any difference between those groups (4.59±1.88
vs. 5.48±2.72 ng/ml, p=0.1). Moreover, serum resistin, but not
adiponectin, correlated with CRP (p<0.02) only in the patients
with EOA.
Conclusions: Increased circulating adiponectin in patients with
EOA compared to non-erosive OA of the hands may be re-
lated to the pathogenesis of joint erosions in patients with OA.
Further studies are necessary to clarify the functional role of
adipocytokines in the pathogenesis of OA.
Supported by Ministry of Health of the Czech Republic - research
project No. 00023728.
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REPRODUCIBILITYOF CYTOKINE BIOMARKER
ASSESSMENTS BETWEEN TWO MULTIPLEX SYSTEMS
D.K. Thompson, J.L. Huebner, R.J. Sloane, V.B. Kraus
Duke University, Durham, NC
Purpose: The purpose of this study was to compare the inter-
and intra-assay reproducibility of cytokine measurements be-
tween two multiplex ELISA technologies, Searchlight (SL, from
Pierce/Endogen) and Luminex (LX, from BioSource/Invitrogen)
in order to validate a method for future studies.
Methods: Fifteen analytes were identiﬁed as potential candi-
dates of interest in various future studies. Nine analytes (BDNF,
GCSF, IL-1ra, IL-2, IL-6, IL-8, IL-10, and VEGF) were avail-
able for both SL and LX. Two additional analytes (Leptin and
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TRAIL) were available only for SL, while four analytes (MCP-
1, RANTES, TNFR1, and TNFR2) were compatible only with
the LX array. Human serum samples (n=18), stored at -80°C,
represented a subset from the OA Life study, whose subjects
were all obese with knee OA. To compare inter- and intra-assay
variability, serum samples were assayed at three separate times.
After the ﬁrst assay, samples were aliquoted and refrozen for
testing on a different day; thus samples tested on days 2 and
3 were identical and differed from those tested on day 1 by
a single freeze/thaw cycle. The reproducibility of measurement
was analyzed by linear regression and by Intra-Class Correlation
(ICC) both between and within the two platform technologies.
Results: Of the nine analytes common to both SL and LX,
all but IL-8 were consistently detectable on SL, and all but
IL-10 were consistently detectable on LX. The concentrations
measured were generally much higher on LX vs. SL (data not
shown). When data were compared between platforms (e.g.
BDNF measured on SL vs LX), the agreement between SL and
LX was quite low, as seen in ICC values of generally less then 0.4
and R2 values generally less then 0.5 (Table 1). When data were
Table 1. Reliability and correlation of values between SearchLight and Luminex
technologies (measured on days 1, 2, and 3)
Analyte ICC R2
BDNF1 -0.057 0.0022
BDNF2 0.209 0.2286
BDNF3 0.094 0.0519
GCSF1 -0.005 0.0074
GCSF2 0.011 0.0015
GCSF3 -0.004 0.0020
IL-1b1 -0.009 0.2494
IL-1b2 0.011 0.1094
IL-1b3 0.006 0.4958
IL-2 1 -0.013 0.1025
IL-2 2 0.021 0.0315
IL-2 3 0.001 0.0048
IL-6 1 0.020 0.3041
IL-6 2 0.013 0.0471
IL-6 3 0.010 0.0584
IL-8 1 -0.030 N/A
IL-8 2 0.010 N/A
IL-8 3 0.000 N/A
IL-10 1 0.940 N/A
IL-10 2 -0.030 0.0028
IL-10 3 0.030 N/A
IL-1ra 1 0.213 0.6018
IL-1ra 2 0.131 0.1950
IL-1ra 3 0.087 0.1282
VEGF 1 0.336 0.1424
VEGF 2 0.077 0.0085
VEGF 3 0.061 0.0041
Table 2. Intra-Class Correlation (ICC) values for various analytes measured
within each system
Analyte Day 1 vs Day 2 Day 1 vs Day 2 Day 2 vs Day 3
vs Day 3
SL LX SL LX SL LX
BDNF -0.1238 0.8190 -0.1869 0.9303 -0.3316 0.8833
GCSF 0.4630 0.9156 0.7031 0.8476 0.1508 0.9585
IL-1b 0.4103 0.7095 0.4856 0.4320 0.2678 0.9403
IL-2 0.2220 0.9682 0.4413 0.9807 -0.0259 0.9819
IL-6 0.5425 0.8524 0.7026 0.7226 0.3116 0.9430
IL-8 -0.0353 0.9578 0.0000 0.9263 -0.0706 0.9869
IL-10 0.8590 0.7326 0.8879 0.5645 0.7705 0.8378
IL-1ra 0.4771 0.9323 0.7157 0.8751 0.2609 0.9690
Leptin 0.4542 N/A 0.5828 N/A 0.2528 N/A
MCP-1 N/A 0.9384 N/A 0.9062 N/A 0.9617
RANTES N/A 0.3001 N/A 0.4874 N/A 0.3455
TNFR1 N/A 0.9065 N/A 0.8267 N/A 0.9820
TNFR2 N/A 0.8575 N/A 0.7915 N/A 0.9703
TRAIL 0.5162 N/A 0.7511 N/A 0.2499 N/A
VEGF 0.1457 0.8887 0.3291 0.7945 -0.0447 0.9696
log-transformed to minimize the potential effect of outliers, ICC
scores remained low. When data were analyzed within platforms
for each analyte (e.g., BDNF measured on LX on day 1 vs. day 2
vs. Day3) ICC values (Table 2) and R2 values (not shown) were
generally higher for analytes measured by LX than by SL.
Conclusions: In anticipation of measuring cytokine levels across
a number of studies and over several years, we sought to validate
a platform technology which would yield reliable measurements.
At a minimum, our goal was to identify a method sensitive enough
to detect the analytes of interest, and consistent enough to result
in lower assay variability than biologic and inter-subject variability.
LX yielded very consistent measurements (ICCs generally > 0.7)
for all of the detectable analytes except RANTES (ICC = 0.3). In
contrast, SL yielded inconsistent measurements (ICCs generally
< 0.4) for all of the analytes except IL-10 (ICC = 0.86). Thus, in
our hands, and with this panel of analytes, LX proved to be the
superior system in terms of assay reliability.
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SERUM PRE-CLINICAL CTX II (CARTILAPS®) ASSAY
VALIDATION USING EQUINE SERUM
T.N. Trumble1, M.P. Brown1, K.A. Merritt1, R.C. Billinghurst2
1University of Florida, Gainesville, FL; 2St. Lawrence College,
Kingston, ON, Canada
Purpose: The CTX II assay has been used to examine the type
II collagen telopeptide concentration in human synovial ﬂuid,
explant media, and urine of rats and humans. These reports
demonstrate that CTX II may be beneﬁcial for diagnosing, pre-
dicting and monitoring changes that occur in osteoarthritis (OA)
patients. Horses are one of the few species in which adequate
volumes of paired synovial ﬂuid, serum, and urine samples can
be collected and compared to allow correlation of this marker
in these different ﬂuids. This may lead to translational beneﬁt to
human OA patients. Type II collagen is well conserved across
species, and the investigators have previously validated the use
of this assay with equine synovial ﬂuid. The purpose was to
validate use of the CTX II assay for use with equine serum for
future use with equine models of OA.
Methods: Serum Pre-Clinical Cartilaps® ELISAs (Nordic Bio-
science Diagnostics) were used according to manufacturer pro-
tocols. Internal quality control (QC) samples were prepared using
the highest concentration standard provided by the manufacturer
(233.3 pg/ml). To create QC samples, fresh serum was collected
aseptically from the jugular vein of 6 normal horses. The samples
were pooled together for further processing and analysis. Pooled
samples were spiked with a known amount of standard to create
samples with high, medium and low levels of CTX II. The QC
samples were used to determine the precision, speciﬁcity, sensi-
tivity, accuracy, linearity of dilution, and stability of this assay with
equine serum. To ensure that the assay could detect different
biological activity, previously stored serum samples were ana-
lyzed from 3 normal horses before (rested) and after 5 months
race-training (exercise), and 3 horses with naturally-occurring
osteochondral (OC) injuries.
Results: Reproducibility of the standard curve was evaluated
(n=6 plates) by computing mean optical density (OD) and per-
cent coefﬁcient of variation (% CV) at each standard concen-
tration. The overall mean inter-assay CV of the standard OD
values was 18.1% (range 11.4-36.9%). Samples exhibited ac-
ceptable intra-assay and inter-assay precision over 3 plates with
an overall mean CV of 4.4% (range; 2.5-9.2%) and 11.9% (range;
10.3-14.4%), respectively. Parallelism and linearity of dilution of
equine serum sample dilutions (1:2, 1:4, 1:8, and 1:10) were
demonstrated (Figure 1). Lowest detection limit of the assay was
determined to be 11.6 pg/ml. Percent recovery was 70% for high,
86% for medium, and 103% for low QC samples. There was no
